To evaluate the safety of rapamycin drug-eluting stent implantation, to analyze occurrence rate and character of stent thrombus following implantation, and to explore risk of stent thrombus event verified by visualization in patients with rapamycin drug-eluting stent.METHODS:
Using computer, self-control articles concerning thrombosis reason analysis and safety of rapamycin drug-eluting stent were retrieved in China National Knowledge Infrastructure (CNKI) from 1997 to 2009, with key words of “rapamycin, drug-eluting stent, bare metal stent, thromrosis in stent”. The data were extracted and analyzed following retrieval.RESULTS:
A total of 12 studies including 3 839 patients undergoing rapamycin drug-eluting stent implantation were in accordance with inclusion criteria. Vascular stenosis rate was decreased following rapamycin drug-eluting stent implantation. Follow-up results showed that the occurrence rate of thomrosis in China-made rapamycin drug-eluting stent and bare metal stent was low, and no significant difference was determined. The restenosis rate of China-made rapamycin drug-eluting stent was significantly lower compared with the bare metal stent. Long-term follow-up results indicated that it is necessary to prolong the duration of antiplatelet treatment.CONCLUSION:
The safety of rapamycin drug-eluting stent implantation, especially thrombus in advanced stage, deserves close attention, but the occurrence rate is very low. Safety, correlation of risk and advantage of rapamycin drug-eluting stent requires reasonable judgment in clinic. Rapamycin drug-eluting stent is better than bare metal stent in treatment of multivessel disease, resulting in a high income and risk rate.